The U.S. Food and Drug Administration (FDA) issued final guidance for industry "Considerations in Demonstrating Interchangeability With a Reference Product” and announced the release in an FDA statement. This guidance is intended to assist sponsors in demonstrating that a proposed therapeutic protein product is interchangeable with a reference product for the purposes of submitting a marketing application or supplement under the Public Health Service Act (PHS Act).
